In this podcast episode, listen to Prof Isabelle Ray-Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on trials of interest including novel HRD testing for ovarian cancer, OS results from ARIEL3, and QoL outcomes for rare nonepithelial ovarian cancers following chemotherapy.
In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:
• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer
• Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test
• Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial
• Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer
Presenters:
Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France
Ignace Vergote, MD, PhD
Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven
Leuven, Belgium
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3SSSqpN